MOUNTAIN VIEW, Calif., Dec. 18 /PRNewswire/ -- Aviron (Nasdaq: AVIR) today
announced that it has filed a universal shelf Registration Statement with the
Securities and Exchange Commission pursuant to which it may offer up to an
aggregate of $400 million of any combination of newly issued common stock and
debt securities in one or more new financing transactions.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
A written prospectus and prospectus supplement, when available, meeting
the requirements of Section 10 of the Securities Act of 1933 may be obtained
from Aviron at 297 North Bernardo Avenue, Mountain View, California 94043.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. This news release
shall not constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.
SOURCE Aviron
 back to top
CONTACT:
media, John Bluth, 650-919-3716, or Asha
Jennings, 650-919-1429, both of Aviron; or Camela Stuby of
Fleishman-Hillard, 212-453-2000, for Aviron; or investors, John
Bluth, 650-919-3716, or Fred Kurland, 650-919-6666, or Asha
Jennings, 650-919-1429, all of Aviron
|
